BridgeBio to Present Phase 3 FORTIFY Trial Data at 2026 MDA Conference
BridgeBio Pharma will present interim analysis data from its Phase 3 FORTIFY trial of BBP-418 for limb-girdle muscular dystrophy at the 2026 MDA conference. The study has met efficacy endpoints, with additional presentations planned from academic collaborators. The company previously announced its Q4 and full year 2025 financial results release date.
BridgeBio Pharma will present additional data from the interim analysis of its Phase 3 FORTIFY clinical trial at the 2026 MDA Clinical and Scientific Conference in Orlando, Florida on March 8-11, 2026. The late-breaking oral presentation will share interim analysis results from the ongoing Phase 3 FORTIFY study of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), which has met efficacy endpoints.
The presentation titled "Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints" will be delivered on Wednesday, March 11 at 2:00 pm ET. Additionally, an oral presentation from BridgeBio's academic collaborators at Yale School of Medicine, along with four posters, will highlight advances in the understanding of BBP-418 and LGMD2I/R9.
The company previously announced it would release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026, followed by a conference call at 4:30 pm ET the same day. BridgeBio is a biopharmaceutical company focused on developing medicines for genetic conditions, aiming to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.